il-17a

IL-17A inhibitor 1 is a IL-17A inhibitor with IC50 of <9.45 nM in alphalisa assay. IL-17A inhibitor 1 inhibits HT-29 cells with IC50 of 9.3 nM.

IL-17A antagonist 1 is an IL-17A antagonist for the study of interleukin-related inflammatory and immune diseases.

IL-17A antagonist 3 is an inhibitor of IL-17A.

IL-17A inhibitor 2 is a compound used for treating psoriasis, rheumatoid arthritis, and multiple sclerosis by inhibiting IL-17A.

IL-17A modulator-1 is an effective inhibitor of IL-17A activity, exhibiting a pIC 50 value of 8.2. This compound holds great promise for studying diseases and disorders that involve the modulation of IL-17A, such as immune-related diseases, autoimmune pathologies, cancer, and neurodegenerative disorders.

IL-17A modulator-2, exhibits inhibitory properties towards IL-17A, with a pIC50 of 8.3. Its effectiveness lies in attenuating the biological effects associated with IL-17A activity. IL-17A modulator-2 finds utility in the study of diseases and disorders characterized by dysregulated IL-17A modulation, such as those involving immune dysfunction, autoimmune pathology, cancer, and neurodegenerative conditions.

IL-17A Inhibitor 4 (Example 449) is an effective inhibitor of IL-17A, exhibiting potent inhibitory effects on both HTRF and NHK cells with IC50 values of 0.028 μM and 0.0047 μM, respectively.

IL-17A Modulator-3, an inhibitor of IL-17A/A, exhibits an IC 50 value of less than 10 μM. It is utilized in research related to inflammation, cancer, and autoimmune diseases.

Anti-Human IL-17A is a fully human anti- interleukin-17A monoclonal antibody. Anti-Human IL-17A can be used for research in psoriasis pathogenesis [1] .

Anti-CTLA-8/IL-17a Antibody is a human-derived antibody expressed by CHO cells, targeting CTLA-8/IL-17a. It features a huIgG1 heavy chain and a huκ light chain, with an estimated molecular weight (MW) of 150 kDa. For isotype control, refer to HumanIgG1kappa, Isotype Control.

Anti-Human/Monkey/Canine IL-17A Antibody (Mab7) is a monoclonal inhibitory antibody targeting human, monkey, and canine IL-17A, applicable to inflammation-related research.

Anti-Mouse IL-17A Antibody (3A7.N) is a monoclonal antibody targeting mouse IL-17A. It can be used for Th17 pathway and inflammation research.

IL-17A Inhibitor 3 (Example 602) serves as an effective inhibitor of IL-17A and holds potential for research in psoriasis treatments.

Vunakizumab (Anti-Human IL17A Recombinant Antibody) is a human IgGκ monoclonal antibody that specifically targets and inhibits IL-17A's receptor interaction, making it useful for researching autoimmune conditions such as psoriatic arthritis, ankylosing spondylitis, multiple sclerosis, and inflammatory arthritis [1].

IL17A-IN-1 (Compound 72) is an orally active inhibitor of Interleukin 17A. This compound is applicable in research related to inflammatory and autoimmune diseases, such as plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and cancer.

Eleutherin, a natural naphthoquinone derivative, exerts protective effects on human umbilical vein endothelial cells (HUVECs) and inhibits carrageenan-induced hyperalgesia in mice.

Anti-Mouse IL-17A Antibody (17F3) is an antibody designed specifically to inhibit mouse IL-17A.

AZD-0284 is an inverse agonist of the nuclear receptor RORγ. In development for the treatment of plaque psoriasis vulgaris and respiratory tract disorders[1].

Dersalazine (Dersalazine Free Base), an inhibitor of platelet-activating factor, exerts intestinal anti-inflammatory activity in different rodent types of colitis by down-regulating IL-17 expression, with potential efficacy in patients with ulcerative colitis.

Ixekizumab (LY2439821) is a humanized IgG4 monoclonal antibody that selectively binds and neutralizes interleukin IL-17A with a Kd value of <3 pM. It blocks the binding of IL-17A to IL-17RA but not to other IL-17 family members. Ixekizumab is used for the treatment of moderate to severe plaque psoriasis, psoriasis, arthritis, and psoriasis.

AX-024 hydrochloride (AX-024 HCl) is an cytokine release inhibitor which can strongly inhibit the production of interleukin-6 (IL-6), tumor necrosis factor-α (TNFα), interferon-γ (IFN-γ), IL-10 and IL-17A.

SGC-CBP30 is an effective CREBBP/EP300 inhibitor (IC50: 21/38 nM).

Xeligekimab (GR 1501) is a fully human monoclonal antibody that selectively neutralizes IL-17A, has potential anti-inflammatory activity, and can be used to study plaque psoriasis.

Netakimab (BCD 085) is a humanized camel-derived monoclonal antibody targeting interleukin-17A, which can be used to study spondyloarthritis and plaque psoriasis.